Domperidone use while Breastfeeding
Domperidone Levels and Effects while Breastfeeding
Summary of Use during Lactation
Domperidone is not approved for marketing in the United States by the US Food and Drug Administration, but is available in Canada and other countries. Domperidone may also be available from some compounding pharmacies in the US. The quality of such products cannot be assured, and the FDA has warned against their use.
Data available from 4 small studies on the excretion of domperidone into breastmilk are somewhat inconsistent, but infants would probably receive less than 0.1% of the maternal weight-adjusted dosage. No adverse effects have been published in a limited number of breastfed infants whose mothers were taking domperidone.
Domperidone is sometimes used as a galactogogue to increase milk supply. Galactogogues should never replace evaluation and counseling on modifiable factors that affect milk production. Most mothers who are provided instruction in good breastfeeding technique and breastfeed frequently are unlikely to obtain additional benefit from domperidone. Whether domperidone has any benefit as a galactogogue in women who continue to have insufficient milk production after nursing technique and frequency have been optimized has not been adequately studied. A meta-analysis of 3 studies that compared domperidone to placebo or no treatment concluded that domperidone increased milk production. However, another meta-analysis of the 2 studies of domperidone in the aforementioned meta-analysis that met strict inclusion criteria for treatment of demonstrated lactation insufficiency in mothers of preterm infants at more than 2 weeks postpartum found that although domperidone increased milk supply acutely, it might not improve long-term outcomes of breastfeeding in this population. Other reviewers concluded that improvement of breastfeeding practices seems more effective and safer than off-label use of domperidone.
Domperidone has no officially established dosage for increasing milk supply. Most published studies have used domperidone in a dosage of 10 mg 3 times daily for 4 to 10 days. Two small studies found no statistically significant additional increase in milk output with a dosage of 20 mg 3 times daily compared to a dosage of 10 mg 3 times daily and that women who failed to respond to the low dosage did not respond to the higher dosage. Dosages greater than 30 mg daily may increase the risk of arrhythmias and sudden cardiac death in patients receiving domperidone, although some feel that the risk is less in nursing mothers because of their relatively younger age. Nevertheless, mothers should be advised to stop taking domperidone and seek immediate medical attention if they experience signs or symptoms of an abnormal heart rate or rhythm while taking domperidone, including dizziness, palpitations, syncope or seizures. Maternal side effects of domperidone reported in galactogogue studies include dry mouth, headache, dizziness, nausea, abdominal cramping, and diarrhea. Some of these were more frequent with 60 mg daily than with 30 mg daily. Drug withdrawal symptoms consisting of insomnia, anxiety, and tachycardia were reported in a woman taking 80 mg of domperidone daily for 8 months as a galactogogue who abruptly tapered the dose over 3 days.
Maternal Levels. Thirty breastmilk samples were obtained from 6 mothers taking domperidone 10 mg 3 times daily and 28 milk samples were obtained from 5 mothers taking domperidone 20 mg 3 times daily. Average concentrations of the drug in breastmilk were 0.28 mcg/L with the lower dosage and 0.49 mcg/L with the higher dosage. The authors estimated that a fully breastfed infant would receive daily dosages of 0.04 and 0.07 mcg/kg daily, respectively, at these maternal dosages. The estimated weight-adjusted maternal dosages were 0.012% and 0.009%, respectively.
A double-blind, controlled trial compared two dosages of domperidone for increasing milk supply in mothers of preterm infants. Mothers received either 10 mg or 20 mg three times daily. Drug concentrations in breastmilk were measured once between days 10 and 15 three hours after a dose. Milk domperidone concentrations were 3.4 mcg/L with the 10 mg dose (n = 4) and 6.9 mcg/L with the 20 mg dose (n = 3).
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
One paper reported 2 studies. In one, 8 women received domperidone 10 mg 3 times daily from day 2 to 5 postpartum. In the other, 9 women One paper reported 2 studies. In one, 8 women received domperidone 10 mg 3 times daily from day 2 to 5 postpartum. In the other, 9 women received domperidone 10 mg 3 times daily for 10 days from week 2 postpartum. No side effects were reported in any of the breastfed (extent not stated) infants.
Eleven women took domperidone 10 mg 3 times daily for 7 days to increase the supply of pumped milk for their preterm neonates. No side effects were reported in their infants.
Effects on Lactation and Breastmilk
Domperidone increases serum prolactin in lactating and nonlactating women. This effect is thought to be caused by the drug's antidopaminergic effect. In nonpregnant women, domperidone is less effective than the same dose of oral metoclopramide in raising serum prolactin; however, in multiparous women their effects are similar. Domperidone has caused galactorrhea in nonpregnant women.
One paper, which was published twice in 2 different journals, reported two separate small studies. In the first study, 15 women with a history of defective lactogenesis were given either oral domperidone 10 mg (n = 8) or placebo (n = 7) 3 times daily from day 2 to 5 postpartum. The patients were apparently not randomized and blinding was not mentioned in the paper. No instruction or support in breastfeeding technique was provided. The groups had similar serum prolactin levels at the start of the study. Baseline serum prolactin levels were higher in the treated women from day 3 to 5 postpartum. Suckling-induced serum prolactin increases were higher in the treated women than in the placebo group from day 2 postpartum onward. Milk yield was calculated by weighing the infants before and after each nursing for 24 hours. Increase in milk yield were greater in the treated mothers from day 2 onward; however, the lower average milk yield in the placebo group was due to 3 women with very low milk output. Average infant weight gain was correspondingly greater in the treated group. At 1 month postpartum, all treated mothers were nursing well, but 5 of 7 untreated mothers had inadequate (not defined) lactation. No correlation was found between baseline serum prolactin or the increase in prolactin and milk production.
In the same paper(s), 17 primiparous women who had insufficient lactation (30% below normal) at 2 weeks postpartum were studied using the same methodology as above. Mothers were given either oral domperidone 10 mg (n = 9) or placebo (n = 8) 3 times daily for 10 days. The groups did not have significantly different serum prolactin levels at the start of the study. Serum prolactin levels were higher in the treated than untreated women from day 2 onward and milk production was higher in the treated group from day 4 onward. At the end of the study no untreated woman had an increase in milk supply from day 1. One month after the beginning of the study, all treated women had adequate milk production. No correlation was found between serum prolactin and milk production.
One well-designed, but small trial was reported with domperidone. Twenty women who were pumping milk with a good quality electric pump for their preterm infants were given either oral domperidone 10 mg (n = 11) or placebo (n = 9) 3 times daily for 7 days in a randomized, double-blind, trial. The mothers averaged 32 to 33 days postpartum. All had failed to produce sufficient milk for their infant after extensive counseling by lactation consultants. By day 5 of therapy, the serum prolactin levels of the treated mothers had increased by 119 mcg/L in the treated group compared to 18 mcg/L in the placebo group. Serum prolactin decreased to baseline levels in both groups 3 days after discontinuation of the study medications. Although the (partially imputed) baseline milk production was greater in the domperidone group (113 mL daily) than in the placebo group (48 mL daily), the average daily increases in milk production on days 2 to 7 were 45% (to 184 mL) and 17% (to 66 mL) in the domperidone and placebo groups, respectively. However, 4 women in the domperidone group failed to complete the study and only the study completers were matched and found to be similar at baseline. No follow-up beyond the 7-day study period was done to evaluate the persistence of an effect of domperidone on lactation success. While this study appears to offer evidence of a beneficial effect on the milk supply in the mothers of preterm infants who are pumping their milk, several factors make this conclusion questionable: a 36% drop-out rate in the active drug group, the lack of an intent-to-treat analysis, and the vast difference in baseline milk supply between the domperidone and placebo groups.
Twenty-five women who had been given domperidone 20 mg 4 times daily to increase milk supply had their dosages decreased over 2 to 4 weeks and discontinued. The duration of domperidone use was not stated in the abstract. All women had stable milk output and were nursing infants under 3 months of age who were growing normally. Of the 25 women, 23 did not increase their use of formula and all infants grew normally, indicating that domperidone can be withdrawn without a detrimental effect on infant nutrition.
Six women who were unable to produce sufficient milk for their preterm infants after counseling by lactation consultants were given domperidone in dosages of 10 mg 3 times daily or 20 mg 3 times daily in a crossover fashion. Baseline serum prolactin concentrations were increased by both dosages to a similar extent. Milk production increased in only 4 of the 6 women. In the other 4 women, milk production increased from 8.7 g/hour at baseline to 23.6 g/hour with 30 mg daily and 29.4 g/hour with 60 mg daily, although there was no statistically significant difference in between the 2 dosages. Side effects in the mothers of dry mouth, abdominal cramping and headache were more frequent with the higher dosage. Severe abdominal cramping caused one mother to drop out of the study during the run-in phase. Additionally, constipation and depressed mood were reported at the higher dosage.
Mothers of preterm infants (<31 weeks) with insufficient milk supply were given either domperidone 10 mg orally 3 times daily or placebo in a randomized, double-blind study. Women who received domperidone had a greater increase in milk volume (+267%) than in the placebo group (19%) at the end of 14 days. Breastmilk calcium concentration increased in the domperidone group (+62%) and decreased (-4%) in the placebo group. Carbohydrate concentrations increased slightly in the mothers receiving domperidone (+2.7%) and decreased slightly (-2.7%) in those receiving placebo. No statistical differences were found in protein, energy, fat, sodium or phosphate concentrations between the groups.
A retrospective, uncontrolled case series reported 14 mothers of preterm infants in the intensive care unit who had been given domperidone 20 mg three times daily to increase their milk supply. The pumped volume of milk increased by 48% over 14 days. However, the lack of a control group renders this report uninterpretable.
Mothers who underwent cesarean section at term were randomized to receive either oral domperidone 10 mg (n = 22) or placebo (n = 23) 4 times daily in a double-blind fashion beginning within the 24 hours postpartum. Nurses collected the mothers' milk with an electric breast pump applied for 15 minutes twice daily 2 hours after the mothers nursed their infants. The volume of milk collected by this incomplete collection technique was greater at all times, including at baseline, in the domperidone group. Seven women in the domperidone group reported dry mouth, and none in the placebo group. Because of the endpoint selected and inequalities at baseline, it is impossible to attribute any clinical relevance to these results.
Mothers who were expressing milk for their infants in a neonatal intensive care unit (mean gestational age 28 weeks) were given instructions on methods for increasing milk supply. If they were producing less than 160 mL of milk per kg of infant weight daily after several days, mothers were randomized to receive either domperidone or metoclopramide 10 mg by mouth 3 times daily for 10 days in a double-blinded fashion. Thirty-one mothers who received domperidone and 34 who received metoclopramide provided data on daily milk volumes during the 10 days. Milk volumes increased over the 10-day period by 96% with domperidone and 94% with metoclopramide, which was not statistically different between the groups. Some mothers continued to measure milk output after the end of the medication period. Results were similar between the 2 groups. Side effects in the domperidone group (3 women) included headache, diarrhea, mood swings and dizziness. Side effects in the metoclopramide group (7 women) included headache (3 women), diarrhea, mood swings, changed appetite, dry mouth and discomfort in the breasts. The lack of a placebo group and the projection of milk volumes to impute missing data from some mothers detract from the findings of this study.
A double-blind, controlled trial compared two dosages of domperidone for increasing milk supply in mothers of preterm infants. Mothers received either 10 mg (n = 8) or 20 mg (n = 7) three times daily for 4 weeks, followed by a tapering dosage over the subsequent 2 weeks. Both dosages increased milk volume, but there was no statistically significant different in milk volumes between the two groups.
A randomized trial in Pakistan compared the effects of domperidone 10 mg to placebo 3 times daily in women who delivered at term and had 10 mL or less of milk production from both breasts per single expression on day 6 postpartum. All women were given some counseling about proper breastfeeding technique. After 7 days of drug or placebo use, women were categorized as having either 50 mL or greater milk production per single expression or less than 50 mL. Serum prolactin was not measured. Seventy-two percent of women given domperidone successfully increased their milk supply compared to 11% in the placebo group. Problems with the study included an apparent lack of blinding of the drugs, investigators and mothers as well as the questionable endpoint of a single expression at an uncontrolled time of day rather than a daily total of milk output.
Alternate Drugs to Consider
1. Anon. FDA warns against women using unapproved drug, domperidone, to increase milk production. FDA Talk Paper. 2004. http://wwwfdagov/bbs/topics/ANSWERS/2004/ANS01292html
2. Winterfeld U, Meyer Y, Panchaud A, Einarson A. Management of deficient lactation in Switzerland and Canada: A survey of midwives' current practices. Breastfeed Med. 2012;7:317-8. PMID: 22224508
3. The Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #9: use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First revision January 2011). Breastfeed Med. 2011;6:41-9. PMID: 21332371
4. Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int. 2012;2012:642893. PMID: 22461793
5. Donovan TJ, Buchanan K. Medications for increasing milk supply in mothers expressing breastmilk for their preterm hospitalised infants. Cochrane Database Syst Rev. 2012;3:CD005544. PMID: 22419310
6. Anderson PO, Valdes V. A critical review of pharmaceutical galactagogues. Breastfeed Med. 2007;2:229-42. PMID: 18081460
7. Paul C, Zenut M, Dorut A et al. Use of domperidone as a galactagogue drug: A systematic review of the benefit-risk ratio . J Hum Lact. 2014. PMID: 25475074
8. Wan EW, Davey K, Page-Sharp M et al. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol. 2008;66:283-9. PMID: 18507654
9. Knoppert DC, Page A, Warren J et al. The effect of two different domperidone dosages on maternal milk production. J Hum Lact. 2013;29:38-44. PMID: 22554679
10. Health Canada endorsed important safety information on domperidone maleate. March 2. 2012. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/domperidone_hpc-cps-eng.php. Accessed May 16, 2012
11. Bozzo P, Koren G, Ito S. Health Canada advisory on domperidone: Should I avoid prescribing domperidone to women to increase milk production? Can Fam Physician. 2012;58:952-3. PMID: 22972723
12. Jantarasaengaram S, Sreewapa P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet. 2012;116:240-3 PMID: 22189066
13. Ingram J, Taylor H, Churchill C et al. Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2012;97:F241-5. PMID: 22147287
14. Papastergiou J, Abdallah M, Tran A, Folkins C. Domperidone withdrawal in a breastfeeding woman. Can Pharm J (Ott). 2013;146:210-2. PMID: 23940477
15. Petraglia F, De Leo V, Sardelli S et al. Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol. 1985;19:281-7. PMID: 3894101
16. De Leo V, Petraglia F, Sardelli S et al. [Use of domperidone in the induction and maintenance of maternal breast feeding]. Minerva Ginecol. 1986;38:311-5. PMID: 3725173
17. da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ. 2001;164:17-21. PMID: 11202662
18. Brouwers JR, Assies J, Wiersinga WM et al. Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Clin Endocrinol (Oxf). 1980;12:435-40. PMID: 7428183
19. Hofmeyr GJ, van Iddekinge B, Blott JA. Domperidone: secretion in breast milk and effect on puerperal prolactin levels. Br J Obstet Gynaecol. 1985;92:141-4. PMID: 3882143
20. Brown TE, Fernandes PA, Grant LJ et al. Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. J Soc Gynecol Investig. 2000;7:65-9. PMID: 10732318
21. Poovathingal MA, Bhat R, Ramamoorthi. Domperidone induced galactorrhea: an unusual presentation of a common drug. Indian J Pharmacol. 2013;45:307-8. PMID: 23833383
22. Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. J Pak Med Assoc. 2010;60:689-90. PMID: 20726208
23. Nijhawan S, Rai RR, Sharma CM. Domperidone induced galactorrhea. Indian J Gastroenterol. 1991;10:113. PMID: 1916962
24. Cann PA, Read NW, Holdsworth CD. Galactorrhoea as side effect of domperidone. Br Med J (Clin Res Ed). 1983;286:1395-6. PMID: 6404476
25. Livingstone V, Blaga Stancheva L, Stringer J. The effect of withdrawing domperidone on formula supplementation. Breastfeed Med. 2007;2:178. Abstract 3 DOI: doi:10.1089/bfm.2007.9985
26. Campbell-Yeo ML, Allen AC, Joseph KS et al. Effect of domperidone on the composition of preterm human breast milk. Pediatrics. 2010;125:e107-14. PMID: 20008425
27. Wagner CL, Murphy PK, Haase B et al. Domperidone in the treatment of low milk supply in mothers of critically ill neonates. Breastfeed Med. 2011;6 (Suppl 1):S-21. Abstract. DOI: doi:10.1089/bfm.2011.9985
28. Inam I, Hashmi AB, Shahid A. A comparison of efficacy of domperidone and placebo among postnatal women with inadequate breast milk production. Pak J Med Health Sci. 2013;7.
CAS Registry Number
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.